Stem Cell Research (May 2020)
Generation of a human induced pluripotent stem cell line, BRCi004-A, derived from a patient with age-related macular degeneration
- Kazuma Kamata,
- Yuki Otsuka,
- Keiko Imamura,
- Akio Oishi,
- Takayuki Kondo,
- Mika Suga,
- Ran Shibukawa,
- Yasue Okanishi,
- Yukako Sagara,
- Kayko Tsukita,
- Tsutomu Yasukawa,
- Hideaki Usui,
- Keiko Muguruma,
- Akitaka Tsujikawa,
- Haruhisa Inoue
Affiliations
- Kazuma Kamata
- iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan
- Yuki Otsuka
- iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Keiko Imamura
- iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, 606-8507, Japan
- Akio Oishi
- Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
- Takayuki Kondo
- iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, 606-8507, Japan
- Mika Suga
- iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Ran Shibukawa
- iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Yasue Okanishi
- iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan
- Yukako Sagara
- iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan
- Kayko Tsukita
- iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Tsutomu Yasukawa
- Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
- Hideaki Usui
- Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
- Keiko Muguruma
- Laboratory for Cell Asymmetry, RIKEN Center for Developmental Biology, Kobe, 650-0047, Japan; Department of iPS Cell Applied Medicine, Graduate School of Medicine, Kansai Medical University, Hirakata, 573-1010, Japan
- Akitaka Tsujikawa
- Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
- Haruhisa Inoue
- iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; Corresponding author:
- Journal volume & issue
-
Vol. 45
Abstract
Age-related macular degeneration (AMD) is a late-onset progressive blinding disease. We established human induced pluripotent stem cells (iPSCs) from an AMD patient. The generated iPSC line showed pluripotency markers and three-germ layer differentiation ability in vitro. This iPSC line will be useful for elucidating the pathomechanisms of and drug discovery for AMD.
